Otsuka Pharmaceutical announced that it has entered into an agreement to acquire Transcend Therapeutics, a clinical-stage biotechnology company focused on rapid-acting treatments for neuropsychiatric disorders, in a deal valued at up to $1.225 billion.
Under the terms of the agreement, Otsuka will pay $700 million upfront at closing, with up to $525 million in additional contingent payments tied to future sales milestones. The transaction is expected to close in the second quarter of 2026, subject to customary conditions.
Founded in 2021, Transcend Therapeutics is developing innovative therapies targeting conditions such as post-traumatic stress disorder (PTSD). Its lead program, TSND-201 (methylone), is a rapid-acting neuroplastogen designed to enhance neural plasticity in the brain. The compound has shown promise as a potential treatment for PTSD and other psychiatric disorders, particularly given the limited number of approved therapies in this space.
TSND-201 works by increasing the release of monoamines, including serotonin, norepinephrine, and dopamine, which enhances synaptic activity and promotes neuroplasticity. Unlike some related compounds, it does not activate the serotonin 5-HT2A receptor associated with hallucinogenic effects, positioning it as a non-hallucinogenic alternative.
The drug has already demonstrated encouraging results in a Phase 2 clinical trial known as IMPACT-1, where patients with severe PTSD experienced rapid and statistically significant improvements compared to placebo. The treatment was generally well tolerated, with side effects such as headache, nausea, and dizziness typically resolving within a day. Based on its clinical profile, TSND-201 received Breakthrough Therapy designation from the U.S. Food and Drug Administration in 2025, and a Phase 3 trial is currently underway.
Otsuka said the acquisition will strengthen its presence in the psychiatric and neurological treatment space, where it has longstanding experience across conditions including schizophrenia, bipolar disorder, depression, and PTSD. The company has also been expanding its pipeline through partnerships and acquisitions, including prior investments in next-generation neuropsychiatric therapies.
With PTSD affecting more than 13 million people annually in the United States and limited treatment options available, Otsuka believes TSND-201 could represent a significant advancement in care. By integrating Transcend’s platform and pipeline, the company aims to accelerate development and bring new therapies to patients with unmet medical needs.
KEY QUOTES:
“We are very pleased to welcome Transcend Therapeutics into the Otsuka group. Although treatment options for PTSD remain limited, TSND-201 is generating expectations as a potential paradigm-shifting therapy in the field of psychiatry. By combining Otsuka’s long-standing expertise in the psychiatric and neurological fields with Transcend’s innovative approach, we will advance the development of TSND-201 in close collaboration with regulatory authorities to bring this new treatment option to patients.”
Makoto Inoue, President And Representative Director Of Otsuka Pharmaceutical Co., Ltd.
“We founded Transcend to bring a fundamentally new treatment to patients with PTSD, one that is rapid-acting and accessible. Otsuka’s leadership and longstanding commitment in neuroscience reflect the same dedication to patients that has driven our team from day one, and we are proud to continue advancing TSND-201 together in service of that shared mission.”
Blake Mandell, CEO And Co-Founder Of Transcend Therapeutics
